BRIEF-Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20
July 25, 2016 at 09:58 AM EDT
* Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.